---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023332"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:54.425025+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab

## Summary
- Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.
- Cash and equivalents $6.2M as of June 30, 2025; expected runway into Q4 2025.
- First patient dosed in Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor tislelizumab (TEVIMBRA).
- Raised ~$5.7M gross via convertible notes and warrants in June 2025; converted to common stock and pre-funded warrants in July.
- Company expects to share initial combination trial data from first cohort later this year.

## SEC filing metadata
- accession: 0001641172-25-023332
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/0001641172-25-023332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023332
- JSON: https://secwatch.observer/filing/0001641172-25-023332.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.